159 related articles for article (PubMed ID: 25461901)
1. Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis).
Bowman CJ; Evans M; Cummings T; Oneda S; Butt M; Hurst S; Gremminger JL; Shelton D; Kamperschroer C; Zorbas M
Reprod Toxicol; 2015 Jun; 53():105-18. PubMed ID: 25461901
[TBL] [Abstract][Full Text] [Related]
2. Morphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor.
Butt M; Evans M; Bowman CJ; Cummings T; Oneda S; Shelton D; Zorbas M
Toxicol Sci; 2014 Dec; 142(2):463-76. PubMed ID: 25326242
[TBL] [Abstract][Full Text] [Related]
3. Reproductive toxicity of denosumab in cynomolgus monkeys.
Bussiere JL; Pyrah I; Boyce R; Branstetter D; Loomis M; Andrews-Cleavenger D; Farman C; Elliott G; Chellman G
Reprod Toxicol; 2013 Dec; 42():27-40. PubMed ID: 23886817
[TBL] [Abstract][Full Text] [Related]
4. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
Enright BP; Tornesi B; Weinbauer GF; Blaich G
Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
[TBL] [Abstract][Full Text] [Related]
5. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys.
Vaidyanathan A; McKeever K; Anand B; Eppler S; Weinbauer GF; Beyer JC
Toxicol Sci; 2011 Jan; 119(1):116-25. PubMed ID: 20937725
[TBL] [Abstract][Full Text] [Related]
6. Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys.
Clarke DO; Hilbish KG; Waters DG; Newcomb DL; Chellman GJ
Reprod Toxicol; 2015 Dec; 58():160-73. PubMed ID: 26482726
[TBL] [Abstract][Full Text] [Related]
7. An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody.
Breslin WJ; Hilbish KG; Martin JA; Halstead CA; Newcomb DL; Chellman GJ
Birth Defects Res B Dev Reprod Toxicol; 2015 Jun; 104(3):100-16. PubMed ID: 26195230
[TBL] [Abstract][Full Text] [Related]
8. From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment.
Belanger P; Butler P; Butt M; Bhatt S; Foote S; Shelton D; Evans M; Arends R; Hurst S; Okerberg C; Cummings T; Potter D; Steidl-Nichols J; Zorbas M
Toxicol Sci; 2017 Aug; 158(2):319-333. PubMed ID: 28525647
[TBL] [Abstract][Full Text] [Related]
9. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.
Boyce RW; Varela A; Chouinard L; Bussiere JL; Chellman GJ; Ominsky MS; Pyrah IT
Bone; 2014 Jul; 64():314-25. PubMed ID: 24727159
[TBL] [Abstract][Full Text] [Related]
10. Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey.
Katagiri R; Ishihara-Hattori K; Frings W; Amano J; Fuchs A; Chiba S
Birth Defects Res; 2017 Jul; 109(11):843-856. PubMed ID: 28504465
[TBL] [Abstract][Full Text] [Related]
11. Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys.
Bellot M; Luetjens CM; Bagger M; Horvath C; Sutter E; DeLise A; Brees D; Carballido JM; Pingili R; Ramanathan K; Kieseier BC; Hellwig K
Reprod Toxicol; 2022 Mar; 108():28-34. PubMed ID: 34942355
[TBL] [Abstract][Full Text] [Related]
12. Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys.
Moriyama T; Kakiuchi D; Grasso L; Hutto DL; Fernando D; Schweizer C
Reprod Toxicol; 2018 Aug; 79():89-95. PubMed ID: 29928988
[TBL] [Abstract][Full Text] [Related]
13. Embryo-fetal developmental toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys.
Bowman CJ; Chmielewski G; Oneda S; Finco D; Boucher MA; Todd M
Birth Defects Res B Dev Reprod Toxicol; 2010 Aug; 89(4):326-38. PubMed ID: 20540090
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Developmental Toxicity of Vedolizumab, an α
Crawford D; Friedman M
Int J Toxicol; 2019; 38(5):395-404. PubMed ID: 31364424
[TBL] [Abstract][Full Text] [Related]
15. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.
Zorbas M; Hurst S; Shelton D; Evans M; Finco D; Butt M
Regul Toxicol Pharmacol; 2011 Mar; 59(2):334-42. PubMed ID: 21130822
[TBL] [Abstract][Full Text] [Related]
16. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.
Martin PL; Sachs C; Imai N; Tsusaki H; Oneda S; Jiao Q; Treacy G
Birth Defects Res B Dev Reprod Toxicol; 2010 Oct; 89(5):351-63. PubMed ID: 20540088
[TBL] [Abstract][Full Text] [Related]
17. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys.
Prell RA; Dybdal N; Arima A; Chihaya Y; Nijem I; Halpern W
Toxicol Sci; 2018 Sep; 165(1):186-197. PubMed ID: 29893934
[TBL] [Abstract][Full Text] [Related]
18. Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates.
Wang H; Schuetz C; Arima A; Chihaya Y; Weinbauer GF; Habermann G; Xiao J; Woods C; Grogan J; Gelzleichter T; Cain G
Reprod Toxicol; 2016 Aug; 63():82-95. PubMed ID: 27211603
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.
Santostefano M; Herzyk D; Montgomery D; Wolf J
Regul Toxicol Pharmacol; 2019 Nov; 108():104476. PubMed ID: 31536773
[TBL] [Abstract][Full Text] [Related]
20. Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.
Stewart J
Reprod Toxicol; 2009 Sep; 28(2):220-5. PubMed ID: 19379807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
